Analysis of responses and outcomes according to dasatinib IC₅₀, based on cellular IC₅₀ values reported by O'Hare et al³  and Redaelli et al.¹⁹ . (A) Time to major cytogenetic response (MCyR). (B) Progression-free survival (PFS). (C) Transformation-free survival (TFS).